Ticker archive · $RXRX

$RXRX Filing Signals & Market Reactions

Delayed, SEO-crawlable recaps of AI-scored catalysts for $RXRX — including observed post-filing price moves. Live streaming stays exclusive to VIP.

? All delayed signals

$RXRX

$RXRX – Recursion Reports Q3 Net Loss Narrowing to $119M, Updates Phase 2 Data

RECURSION PHARMACEUTICALS, INC.

2026-11-02 00:00:00 UTC · SEC_8K · All $RXRX

?? Positive AI Sentiment (+3.0 / 10)

Total Q3 revenue rose to $18.55M from $5.18M YoY; net loss narrowed to $119.0M ($0.22/share) vs $162.3M ($0.36/share).
Positive Phase 2 REC-4881 data presented showing durable polyp burden reductions in FAP.
Cash and cash equivalents stood at $549.9M at quarter-end with extended runway.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?